Fosun Pharmaceutical, a leading healthcare group on the mainland, plans to focus on early diagnosis and cost-effective treatment of cancer by using the world’s latest technologies such as robotic-assisted medical devices. Chen Qiyu, chairman of Shanghai-based Fosun Pharma, a subsidiary of the mainland’s largest non-state-owned investment conglomerate Fosun Group, said the company would introduce advanced technologies available in the United States to the Chinese market.